ENFN Investors Have Opportunity to Join Enfusion, Inc. Securities Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. (“Enfusion” or “the Company”) (NYSE: ENFN) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Enfusion reported its financial results for the second quarter of 2024 on August 6, 2024. The Company missed consensus estimates for both earnings and revenue. Based on this news, shares of Enfusion fell by 7.86% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904862746/en/
The Enfusion Registered (A) Stock at the time of publication of the news with a fall of -0,50 % to 8,02USD on NYSE stock exchange (04. September 2024, 23:05 Uhr).